Elanco Animal Health (ELAN) Total Non-Current Liabilities (2017 - 2026)
Elanco Animal Health's (ELAN) quarterly Total Non-Current Liabilities came in at $6.3 billion in Q1 2026, up 2.52% year-on-year from $6.1 billion in Q1 2025, and little changed quarter-over-quarter from $6.2 billion in Q4 2025.
Elanco Animal Health (ELAN) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Elanco Animal Health has disclosed Total Non-Current Liabilities across 10 years of filings, most recently posting $6.3 billion for Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $6.3 billion, up 2.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.3 billion (up 2.52% YoY), and the FY2025 annual result was $6.2 billion, changed 0.16% from the prior year.
- Total Non-Current Liabilities came in at $6.3 billion for Q1 2026 at Elanco Animal Health, roughly flat from $6.2 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $8.4 billion in Q1 2022 to a low of -$183.0 million in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $7.4 billion (2024), against an average of $6.7 billion.
- Across the five-year window, Total Non-Current Liabilities tumbled 102.12% in 2022 and soared 4452.46% in 2023, its largest moves.
- Elanco Animal Health's Total Non-Current Liabilities stood at $8.0 billion in 2022, then slipped by 3.07% to $7.7 billion in 2023, then fell by 19.57% to $6.2 billion in 2024, then advanced by 0.16% to $6.2 billion in 2025, then rose by 0.47% to $6.3 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $6.3 billion (Q1 2026), $6.2 billion (Q4 2025), and $6.2 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.13 Bn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 1.81 Bn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.26 Bn |
| Dec 31, 2025 | 6.23 Bn |
| Sep 30, 2025 | 6.20 Bn |
| Jun 30, 2025 | 6.33 Bn |
| Mar 31, 2025 | 6.10 Bn |
| Dec 31, 2024 | 6.22 Bn |
| Sep 30, 2024 | 6.17 Bn |
| Jun 30, 2024 | 7.36 Bn |
| Mar 31, 2024 | 7.49 Bn |
| Dec 31, 2023 | 7.73 Bn |
| Sep 30, 2023 | 7.78 Bn |
| Jun 30, 2023 | 7.97 Bn |
| Mar 31, 2023 | 8.04 Bn |
| Dec 31, 2022 | 7.97 Bn |
| Sep 30, 2022 | 7.98 Bn |
| Jun 30, 2022 | -183.00 Mn |
| Mar 31, 2022 | 8.40 Bn |
| Dec 31, 2021 | 8.71 Bn |
| Sep 30, 2021 | 8.66 Bn |
| Jun 30, 2021 | 8.62 Bn |